• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtech stories we missed this week: May 26, 2017

May 26, 2017 By Danielle Kirsh

missed medtech
[Image from unsplash.com]
From Merck’s new licensing agreement to surgical study data being touted, here are medtech stories we missed this week but thought were still worth mentioning.

1. Merck inks exclusive licensing agreement for Alzheimer’s antibody

Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufacture and commercialize the anti-tau antibody while Teijin Pharma will receive an upfront payment for development, regulatory and sales milestone payments. Teijin Pharma will also get royalties on product sales.

2. Thermi wins Brazilian nod for ThermiRF

Thermi has received regulatory clearance in Brazil to market and distribute its ThermiRF, according to a May 25 press release. ThermiRF is a temperature-controlled radiofrequency platform that can be used for a variety of aesthetic applications. MedSystems will also help Thermi expand its technology worldwide.

3. Life Spine receives approval for its new study

Life Spine announced in a May 17 press release that it has received approval for its open versus minimally invasive posterior lumbar spine surgery study. The study intended to help determine the outcomes of the surgery and which procedure is less traumatic to the patient while using Life Spine’s Nautilus Thoracolumbar Pedicle Screw System and Centerline Thoracolumbar Cortical Screw System. The study also wants to demonstrate muscular injury and recovery by comparing baseline preoperative electrodiagnostic functional assessment to postoperative tests to determine which surgical techniques resulted in faster recovery.

Get the full story on our sister site, MassDevice.

Filed Under: Clinical Trials, Diabetes, Diagnostics, Featured, Patient Monitoring, Pharmaceuticals, Regulatory/Compliance, Research & Development Tagged With: earlysense, Janssen Pharmaceuticals, Life Spine Inc., Masimo, medtech, Merck, Midmark, Procept BioRobotics, Shenzhen Lachesis Mhealth, Teijin Pharma, Thermi

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS